Category: MS Research Study and Reports

Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study

Christoph Friedli 1 2, Nik Krajnc 3 4, Helly N Hammer 1, Stefanie Marti 1, Tobias Zrzavy 3 4, Maria E Evangelopoulos 5, Ioanna Kapsali 5, Paulus Rommer 3 4, Thomas Berger 3 4, Andrew Chan 1, Gabriel Bsteh 3 4, Robert Hoepner 1 Affiliations expand Abstract Introduction: Patients with Multiple…

Stuart Schlossman

Featured image for “Multiple Sclerosis: Can a Blood Test Detect MS Years Before Symptoms Appear? New Research Encouraging”

Multiple Sclerosis: Can a Blood Test Detect MS Years Before Symptoms Appear? New Research Encouraging

Written By: John Fernandez Published: May 1, 2024 Disponible en Español New clinical trial findings could advance the early treatment for patients…

Stuart Schlossman

Featured image for “‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’”

‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’

In Phase 2 trials, drinkable medication with gold nanocrystals significantly reduced symptoms  By Melissa Rudy Fox News – Published April 30, 2024 5:30am…

Stuart Schlossman

Featured image for “A Smoldering Process: A New Way of Thinking about Multiple Sclerosis”

A Smoldering Process: A New Way of Thinking about Multiple Sclerosis

Published on: October 4, 2023 Our understanding of the biology of multiple sclerosis is changing. New research sheds light on…

Stuart Schlossman

Featured image for “PET scans reveal ‘smoldering’ inflammation in patients with MS”

PET scans reveal ‘smoldering’ inflammation in patients with MS

April 26, 2024 A new study suggests positron emission tomography brain scans could reveal hidden inflammation in patients with multiple…

Stuart Schlossman

Featured image for “Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)”

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)

April 17, 2024 Download PDF New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis…

Stuart Schlossman

Featured image for “Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis”

Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis

Apr 17, 2024 EAST HANOVER, N.J., April 17, 2024 — Novartis today announced data from the ALITHIOS open-label extension study showing sustained…

Stuart Schlossman

Apr 16, 2024 – Press Release: Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Media / Press Releases Tuesday, Apr 16, 2024 Results from the Phase III study showed that subcutaneous (SC) injection was consistent with…

Stuart Schlossman

Redefining Relapse in Efficacy Measures for Multiple Sclerosis Treatments

By: Stephen Krieger, MD; Enrique Alvarez, MD, PhD In this poster, Enrique Alvarez, MD, PhD., (from university of Colorado at…

Stuart Schlossman

Featured image for “Will Frexalimab replace the anti-CD20s?”

Will Frexalimab replace the anti-CD20s?

It is clear to me, and it should be clear to my colleagues, that anti-CD20 therapies have a limited shelf-life…

Stuart Schlossman

Categories

Latest Blog Posts